SCHEMBL6946348

SCHEMBL6946348

CCn1c(C)nc(N2CCc3ccccc3CC2)c([N+](=O)[O-])c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.42
HTT P42858 3/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 2/20 0.42
ALDH1A1 P00352 2/20 0.42
RAB9A P51151 2/20 0.42
MITF O75030 1/20 0.42
AGTR1 P30556 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TLR9 Q9NR96 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
CYP2C9 P11712 2/20 0.39
CYP2D6 P10635 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C19 P33261 1/20 0.39
GPR55 Q9Y2T6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6952584 0.91 CYP2C9 (0.40) MAPTHTTLMNANPC1ALDH1A1
SCHEMBL6952822 0.89 CYP2C9 (0.39) MAPTHTTSMN1; SMN2CYP2C9CYP2D6
SCHEMBL6948557 0.88 MAPT (0.42) MAPTHTTLMNANPC1ALDH1A1
SCHEMBL6953752 0.88 CYP2C9 (0.40) MAPTHTTLMNAALDH1A1RAB9A
SCHEMBL6952446 0.88 CYP2C9 (0.38) MAPTHTTNPC1ALDH1A1RAB9A
SCHEMBL6952859 0.88 CYP2C9 (0.40) MAPTHTTLMNANPC1ALDH1A1
SCHEMBL6950705 0.87 MAPT (0.40) MAPTHTTLMNANPC1ALDH1A1
SCHEMBL6947618 0.87 CYP2C9 (0.37) MAPTHTTLMNANPC1RAB9A
SCHEMBL6950026 0.87 GRIN1 (0.37) MAPTHTTLMNANPC1ALDH1A1
SCHEMBL6434778 0.86 CYP2C9 (0.34) MAPTHTTLMNANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP claimed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US claimed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP claimed
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
JP-2001089472-A 1,2,4,5-TETRAHYDRO-BENZ[d]AZEPINES F HOFFMANN LA ROCHE AG 2001-04-03 JP disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed